Category: Treatment Updates

OPDIVO™ is the first and only immuno-oncology therapy in lung cancer in Canada, which uses the body's own immune system to fight cancer, offering improved survival to more patients MONTREAL, March 1, 2016 /CNW/ – Health Canada has approved OPDIVO™ (nivolumab) injection, the first and only immuno-oncology therapy (anti PD-1 agent) approved in Canada for the treatment of adult patients with locally advanced or metastatic

Mississauga, ON. (January 12, 2016) – Amgen Canada Inc., today announced that Health Canada has granted conditional* approval of BLINCYTO™ (blinatumomab) for the treatment of adults with Philadelphia chromosome-negative (Ph-) relapsed or refractory B precursor acute lymphoblastic leukemia (ALL). With this approval, BLINCYTO™ becomes the first Health Canada-approved bispecific CD19-directed CD3 T-cell engager (BiTE®) antibody construct product, and the first single-agent immunotherapy to be approved

Ontario patients living with CLL and SLL who are eligible will now have access to IMBRUVICA® under the Exceptional Access Program of the Ontario Drug Benefit Program. Eligibility criteria include those patients who: have CLL/SLL and have received at least one prior therapy to treat CLL/SLL; and, are inappropriate for treatment or retreatment with a fludarabine-based regimen. To determine whether patients qualify for IMBRUVICA® treatment

TORONTO, ON, July 27, 2015 – Men in Quebec are one step closer to accessing Xofigo (radium Ra 223 dichloride), for the treatment of castration-resistant prostate cancer (CRPC) with symptomatic bone metastases and no known visceral metastatic disease, thanks to a recent announcement by the Quebec government. Xofigo will be included on the Quebec Liste des médicaments – Établissements, giving hospitals the ability to provide